Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug clear fluid from lungs in heart failure?

NCT ID NCT07076615

Disease control Sponsor: May Mohamed Abdalla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether adding dapagliflozin—a drug commonly used for diabetes—to standard diuretic treatment helps adults hospitalized with acute heart failure. The goal is to see if it reduces fluid buildup in the lungs (measured by ultrasound), shortens hospital stays, and improves heart and kidney function. Half of the 100 participants will receive dapagliflozin plus diuretics, while the other half receives diuretics alone. The study aims to find out if this combination can ease symptoms and speed up recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (an SGLT2 inhibitor) taken as a 10 mg tablet once daily, added to standard intravenous diuretic therapy
What this could lead to
If effective, adding dapagliflozin early during a heart failure hospitalization could speed up recovery, reduce lung fluid, and shorten hospital stays.
What could go wrong
This is a single-center trial with 100 patients, so results may not apply broadly. Dapagliflozin can cause side effects like dehydration, urinary infections, or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Aug 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Acute heart failure as defined by the 2022 American College of Cardiology/American Heart Association (Heidenreich et al., 2022) or 2021 European Society of Cardiology (McDonagh et al., 2021) guidelines, based on typical symptoms and signs of heart failure requiring hospitalization or emergency department visit * Elevated natriuretic peptide levels * Includes heart failure with reduced, mildly reduced, or preserved ejection fraction * Planned use of intravenous diuretic therapy Exclusion Criteria: * Type 1 diabetes mellitus * Urinary tract or genital infection * Hypovolemia * Diabetic ketoacidosis * Serum glucose \< 80 mg/dL at enrollment * Systolic blood pressure \< 90 mmHg at enrollment * History of hypersensitivity to any SGLT2 inhibitor * Pregnant or breastfeeding women * Severe primary valvular lesion requiring intervention * Severe hepatic impairment (Child-Pugh class C) * Estimated glomerular filtration rate \< 25 mL/min/1.73 m² (by MDRD equation)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure (ADHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure (ADHF)

Contacts and locations

Locations

  • Cairo University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.